Ana Maria Guevara
Publications 4
#1Ana Maria GuevaraH-Index: 3
#2Eugenio Suarez (University of Chile)H-Index: 4
Last.Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
view all 10 authors...
ABSTRACTBackground: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who receiv...
#1Ángela María Ruiz Sternberg (Del Rosario University)H-Index: 5
#2Edson D. Moreira (Obras Sociais Irmã Dulce)H-Index: 9
Last.Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
view all 24 authors...
Moreira Junior, Edson Duarte. Associacao Obras Sociais Irma Dulce / Fundacao Oswaldo Cruz. Centro de Pesquisas Goncalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogota, Colombia b Associacao Obras Sociais Irma Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellin, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Lib...
4 CitationsSource
#1Ana Maria GuevaraH-Index: 3
#2Robinson CabelloH-Index: 2
Last.Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
view all 10 authors...
Abstract Background The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characte...
7 CitationsSource
#2Anna R. GiulianoH-Index: 67
Last.Susan S. Kaplan (MSD: Merck & Co.)H-Index: 5
view all 11 authors...
Abstract Objectives This study was designed to evaluate the immunogenicity and tolerability of a prophylactic 9-valent HPV (types 6/11/16/18/31/33/45/52/58) VLP (9vHPV) vaccine in young men 16–26 years of age in comparison to young women 16–26 years of age (the population that was used to establish 9vHPV vaccine efficacy). Safety and immunogenicity data from this study will be used to bridge 9vHPV vaccine efficacy findings in 16–26 year old women to 16–26 year old men. Methods This study enrolle...
55 CitationsSource